Is GNLX or MDXH more profitable?

Genelux has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Genelux's return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% MDxHealth -33.46% N/A -24.25%

Do analysts prefer TLSA or MDXH?

MDxHealth has a consensus target price of $2.17, indicating a potential upside of 281.46%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than Tiziana Life Sciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tiziana Life Sciences 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MDxHealth 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable valuation and earnings, TLSA or MDXH?

Tiziana Life Sciences has higher earnings, but lower revenue than MDxHealth. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tiziana Life Sciences N/A N/A -$18.43M N/A N/A MDxHealth $107.88M 0.26 -$33.52M -$0.72 N/A

Is TLSA or MDXH more profitable?

Tiziana Life Sciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. Company Net Margins Return on Equity Return on Assets Tiziana Life Sciences N/A N/A N/A MDxHealth -33.46% N/A -24.25%

MDxHealth (MDXH) Competitors

$0.57 -0.01 (-2.41%)

As of 02:17 PM Eastern

Compare

MDXH vs. COYA, GNLX, TLSA, BDTX, and RANI

Should you buy MDxHealth stock or one of its competitors? MDxHealth's main competitors and comparable companies include Coya Therapeutics (COYA), Genelux (GNLX), Tiziana Life Sciences (TLSA), Black Diamond Therapeutics (BDTX), and Rani Therapeutics (RANI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MDxHealth compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations.

39.8% of Coya Therapeutics shares are held by institutional investors. 6.1% of Coya Therapeutics shares are held by company insiders. Comparatively, 1.7% of MDxHealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Coya Therapeutics had 1 more articles in the media than MDxHealth. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.89 beat Coya Therapeutics' score of 0.61 indicating that MDxHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Coya Therapeutics	Positive
MDxHealth	Positive

Coya Therapeutics has higher earnings, but lower revenue than MDxHealth. Coya Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	15.02	-$21.23M	-$1.07	N/A
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A

Coya Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 201.24%. MDxHealth has a consensus target price of $2.17, suggesting a potential upside of 281.46%. Given MDxHealth's higher probable upside, analysts plainly believe MDxHealth is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

MDxHealth has a net margin of -33.46% compared to Coya Therapeutics' net margin of -270.22%. MDxHealth's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-270.22%	-52.05%	-46.34%
MDxHealth	-33.46%	N/A	-24.25%

Coya Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Summary

MDxHealth beats Coya Therapeutics on 9 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Genelux?

Genelux (NASDAQ:GNLX) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

In the previous week, Genelux had 4 more articles in the media than MDxHealth. MarketBeat recorded 5 mentions for Genelux and 1 mentions for MDxHealth. Genelux's average media sentiment score of 1.09 beat MDxHealth's score of 0.89 indicating that Genelux is being referred to more favorably in the media.

Company	Overall Sentiment
Genelux	Positive
MDxHealth	Positive

Genelux has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market.

Genelux has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Genelux's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
MDxHealth	-33.46%	N/A	-24.25%

37.3% of Genelux shares are owned by institutional investors. 7.5% of Genelux shares are owned by company insiders. Comparatively, 1.7% of MDxHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Genelux currently has a consensus target price of $18.00, indicating a potential upside of 630.22%. MDxHealth has a consensus target price of $2.17, indicating a potential upside of 281.46%. Given Genelux's stronger consensus rating and higher probable upside, research analysts plainly believe Genelux is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Genelux has higher earnings, but lower revenue than MDxHealth. Genelux is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,151.66	-$32.15M	-$0.86	N/A
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A

Summary

Genelux beats MDxHealth on 10 of the 16 factors compared between the two stocks.

How does MDxHealth compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Tiziana Life Sciences has higher earnings, but lower revenue than MDxHealth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A

Tiziana Life Sciences has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
MDxHealth	-33.46%	N/A	-24.25%

MDxHealth has a consensus target price of $2.17, indicating a potential upside of 281.46%. Given MDxHealth's stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Tiziana Life Sciences has a beta of 0.52, meaning that its share price is 48% less volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

In the previous week, Tiziana Life Sciences had 8 more articles in the media than MDxHealth. MarketBeat recorded 9 mentions for Tiziana Life Sciences and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.89 beat Tiziana Life Sciences' score of 0.27 indicating that MDxHealth is being referred to more favorably in the news media.

Company	Overall Sentiment
Tiziana Life Sciences	Neutral
MDxHealth	Positive

Summary

MDxHealth beats Tiziana Life Sciences on 6 of the 10 factors compared between the two stocks.

How does MDxHealth compare to Black Diamond Therapeutics?

Black Diamond Therapeutics (NASDAQ:BDTX) and MDxHealth (NASDAQ:MDXH) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

Black Diamond Therapeutics currently has a consensus price target of $10.25, indicating a potential upside of 449.60%. MDxHealth has a consensus price target of $2.17, indicating a potential upside of 281.46%. Given Black Diamond Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Black Diamond Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Black Diamond Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 1.7% of MDxHealth shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Black Diamond Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Black Diamond Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Black Diamond Therapeutics	N/A	-32.10%	-25.21%
MDxHealth	-33.46%	N/A	-24.25%

Black Diamond Therapeutics has a beta of 3.31, meaning that its stock price is 231% more volatile than the broader market. Comparatively, MDxHealth has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market.

Black Diamond Therapeutics has higher earnings, but lower revenue than MDxHealth. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Black Diamond Therapeutics	$70M	1.53	$22.37M	-$0.75	N/A
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A

In the previous week, Black Diamond Therapeutics and Black Diamond Therapeutics both had 1 articles in the media. Black Diamond Therapeutics' average media sentiment score of 1.86 beat MDxHealth's score of 0.89 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Black Diamond Therapeutics	Very Positive
MDxHealth	Positive

Summary

Black Diamond Therapeutics beats MDxHealth on 10 of the 15 factors compared between the two stocks.

How does MDxHealth compare to Rani Therapeutics?

MDxHealth (NASDAQ:MDXH) and Rani Therapeutics (NASDAQ:RANI) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

MDxHealth has a beta of 1.57, suggesting that its stock price is 57% more volatile than the broader market. Comparatively, Rani Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market.

MDxHealth currently has a consensus price target of $2.17, indicating a potential upside of 281.46%. Rani Therapeutics has a consensus price target of $8.75, indicating a potential upside of 1,058.94%. Given Rani Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Rani Therapeutics is more favorable than MDxHealth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MDxHealth	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Rani Therapeutics had 3 more articles in the media than MDxHealth. MarketBeat recorded 4 mentions for Rani Therapeutics and 1 mentions for MDxHealth. MDxHealth's average media sentiment score of 0.89 beat Rani Therapeutics' score of 0.70 indicating that MDxHealth is being referred to more favorably in the media.

Company	Overall Sentiment
MDxHealth	Positive
Rani Therapeutics	Positive

Rani Therapeutics has lower revenue, but higher earnings than MDxHealth. Rani Therapeutics is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MDxHealth	$107.88M	0.26	-$33.52M	-$0.72	N/A
Rani Therapeutics	$1.63M	64.57	-$29.67M	-$0.27	N/A

30.2% of Rani Therapeutics shares are owned by institutional investors. 1.7% of MDxHealth shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Rani Therapeutics has a net margin of 0.00% compared to MDxHealth's net margin of -33.46%. MDxHealth's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MDxHealth	-33.46%	N/A	-24.25%
Rani Therapeutics	N/A	-104.60%	-65.17%

Summary

Rani Therapeutics beats MDxHealth on 11 of the 17 factors compared between the two stocks.

Get MDxHealth News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDXH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDXH vs. The Competition

Export

Metric	MDxHealth	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$28.12M	$3.91B	$7.25B	$13.16B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-0.79	14.06	274.69	25.81
Price / Sales	0.26	1,318.94	681.05	110.54
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	-2.37	15.30	10.45	6.32
Net Income	-$33.52M	-$22.86M	$3.48B	$359.77M
7 Day Performance	-9.84%	-3.03%	-1.33%	-0.15%
1 Month Performance	-27.99%	-9.12%	-4.58%	-4.08%
1 Year Performance	-86.79%	31.34%	16.32%	6.16%

MDxHealth Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDXH MDxHealth	2.8259 of 5 stars	$0.57 -2.4%	$2.17 +281.5%	-86.7%	$28.12M	$107.88M	N/A	364
COYA Coya Therapeutics	2.0102 of 5 stars	$5.30 +7.1%	$15.33 +189.3%	-6.8%	$116.12M	$7.95M	N/A	8	Analyst Forecast High Trading Volume
GNLX Genelux	2.7359 of 5 stars	$2.61 +2.0%	$18.00 +589.7%	-44.4%	$115.83M	$10K	N/A	26
TLSA Tiziana Life Sciences	1.5619 of 5 stars	$0.89 -1.6%	N/A	-47.2%	$115.12M	N/A	N/A	10	Analyst Forecast
BDTX Black Diamond Therapeutics	3.3174 of 5 stars	$1.98 +1.5%	$10.25 +417.7%	-42.0%	$112.04M	$70M	N/A	21

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MDXH) was last updated on 9/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MDxHealth (MDXH) Competitors

MDXH vs. COYA, GNLX, TLSA, BDTX, and RANI

How does MDxHealth compare to Coya Therapeutics?

Summary

How does MDxHealth compare to Genelux?

Summary

How does MDxHealth compare to Tiziana Life Sciences?

Summary

How does MDxHealth compare to Black Diamond Therapeutics?

Summary

How does MDxHealth compare to Rani Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MDxHealth (MDXH) Competitors

MDXH vs. COYA, GNLX, TLSA, BDTX, and RANI

How does MDxHealth compare to Coya Therapeutics?

Do insiders & institutionals believe in COYA or MDXH?

Does the media prefer COYA or MDXH?

Which has higher valuation and earnings, COYA or MDXH?

Do analysts rate COYA or MDXH?

Is COYA or MDXH more profitable?

Which has more volatility and risk, COYA or MDXH?

Summary

How does MDxHealth compare to Genelux?

Does the media prefer GNLX or MDXH?

Which has more risk and volatility, GNLX or MDXH?

Is GNLX or MDXH more profitable?

Do insiders & institutionals believe in GNLX or MDXH?

Do analysts recommend GNLX or MDXH?

Which has higher earnings and valuation, GNLX or MDXH?

Summary

How does MDxHealth compare to Tiziana Life Sciences?

Which has preferable valuation and earnings, TLSA or MDXH?

Is TLSA or MDXH more profitable?

Do analysts prefer TLSA or MDXH?

Which has more risk and volatility, TLSA or MDXH?

Does the media refer more to TLSA or MDXH?

Summary

How does MDxHealth compare to Black Diamond Therapeutics?

Do analysts rate BDTX or MDXH?

Do institutionals and insiders believe in BDTX or MDXH?

Is BDTX or MDXH more profitable?

Which has more risk & volatility, BDTX or MDXH?

Which has stronger valuation and earnings, BDTX or MDXH?

Does the media favor BDTX or MDXH?

Summary

How does MDxHealth compare to Rani Therapeutics?

Which has more volatility and risk, MDXH or RANI?

Do analysts rate MDXH or RANI?

Does the media favor MDXH or RANI?

Which has higher valuation and earnings, MDXH or RANI?

Do institutionals & insiders believe in MDXH or RANI?

Is MDXH or RANI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MDXH vs. The Competition

MDxHealth Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools